1. Systemic active immunotherapy is shifting from the middle ages to a renaissance period

   • G. Mathé
   • L. Olsson

   Editorial Pages: 197 - 199

2. The effects of Muramyldipeptide (MDP) in cell-mediated immunity

   • A. Matter

   Original Articles Pages: 201 - 210

3. Circulating immune complexes as possible cause for anticomplementary activity in humans with malignant melanoma

   • R. K. Gupta
   • A. N. Theofilopoulos
   • D. L. Morton

   Original Articles Pages: 211 - 221

4. Immunotherapy of lung cancer with Corynebacterium parvum

   • Houshang Moayeri
   • Hiroshi Takita
   • J. E. Sokal

   Original Articles Pages: 223 - 226

5. Prognostic significance of cell surface phenotype in adult acute lymphoblastic leukaemia

   • T. A. Lister
   • M. M. Roberts
   • M. F. Greaves

   Original Articles Pages: 227 - 230

6. A phase III comparison of methyl-CCNU + vincristine with or without BCG + allogeneic tumor cells in metastatic melanoma

   • M. J. Mastrangelo
   • R. E. Bellet
   • D. Berd

   Original Articles Pages: 231 - 236

7. Influence of BM 12.531 (Prop. INN azimexon) on the lymphocyte transformation and the percentage of active T lymphocytes in vivo and in vitro in man

   • D. Boerner
   • U. Bicker
   • H. J. Peters

   Original Articles Pages: 237 - 242

8. Immunotherapy of osteogenic sarcoma with transfer factor

   • Vera S. Byers
   • L. LeCam
   • Adeline J. Hackett

   Original Articles Pages: 243 - 253

9. Combined immunostimulation in the prevention of tumor take in mice using endotoxins, their derivatives, and other immune adjuvants

   • R. C. Butler
   • A. Nowotny

   Original Articles Pages: 255 - 262

10. Agranulocytosis and tumoural facilitation induced by levamisole in a case of IgG multiple myeloma

    • C. Focan

    Letter To The Editor Pages: 263 - 264

11. Erratum

    Erratum Pages: 265 - 265